Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
BMS Files Hypertrophic Cardiomyopathy Drug in Japan
Bristol Myers Squibb said on July 17 that it has submitted a new drug application in Japan for mavacamten, known with the brand name of Camzyos overseas, for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is an allosteric and…
To read the full story
Related Article
BUSINESS
- 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
- Redasemtide Delivers Mixed PII Results in Stroke, DEB
September 10, 2026
- Sandoz Readies Multiple Biosimilar Launches in Japan for 2027
September 10, 2026
- Kyowa Kirin Says Strong Low-Dose Effect Behind KHK4951 PII Miss
September 10, 2026
- Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…